Jay Starkey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jay Starkey has a total of 215 co-authors. Here are the top co-authors by number of shared publications:
- Shoichi Maeda
Graduate School of Health Management, Keio University, 4411 Endo, Fujisawa, Kanagawa, 252-8530, Japan
6 shared publications Noriaki Ikeda
5 shared publications- Ramon Francisco Barajas
Translational Oncology Program, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA
4 shared publications Taiki Nozaki
4 shared publications- Taiki Nozaki
Department of Radiology, Keio University School of Medicine, Tokyo 160-8582, Japan
4 shared publications Yukihisa Saida
From the Departments of Radiology (T.N., S.H., J.O., J.S., Y.S.) and Orthopaedic Surgery (A.T.), St Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo 104-8560, Japan; Department of Radiological Sciences, University of California, Irvine, Calif (T.N., H.Y.); and Department of Intelligent Image Information, Division of Regeneration and Advanced Medical Sciences, Gifu University Graduate School of Medicine, Gifu, Japan (T.H.).
4 shared publications
Latest Publications
- 1 August 2026
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 46 (8) , e250156
Targeted Neurosurgical Interventions: The Role of Neuroimaging in High-Intensity Focused Ultrasound, Laser Interstitial Thermal Therapy, and Deep Brain Stimulation
High-intensity focused ultrasound, laser interstitial thermal therapy, and deep brain stimulation are minimally invasive neurosurgical techniques that offer targeted mechanism-specific treatment of neurological disorders and represent a shift toward precise imaging-driven intervention.
- 1 August 2026
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 46 (8) , e250156
Targeted Neurosurgical Interventions: The Role of Neuroimaging in High-Intensity Focused Ultrasound, Laser Interstitial Thermal Therapy, and Deep Brain Stimulation
High-intensity focused ultrasound, laser interstitial thermal therapy, and deep brain stimulation are minimally invasive neurosurgical techniques that offer targeted mechanism-specific treatment of neurological disorders and represent a shift toward precise imaging-driven intervention.
- Open Access
- 1 December 2025
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 47 (6) , 1578-1586
Clinical Utility of [ 18 F]-Fluciclovine PET/MRI for Differentiating True Progression from Treatment-Related Changes in Patients with Glioblastoma
BACKGROUND AND PURPOSE: Differentiating true progression from treatment-related changes in patients with glioblastoma (GBM) remains a major diagnostic challenge. Amino acid PET tracers such as [F18]-Fluciclovine provide biologically specific information, but clinical real-world validation across institutions is limited. We aimed to evaluate the clinical diagnostic performance of [F18]-Fluciclovine PET/MRI for distinguishing true progression from treatment-related change in patients with presumed GBM progression across 2 academic centers. MATERIALS AND METHODS: In this retrospective, multi-institutional, IRB-approved study, we analyzed [F18]-Fluciclovine PET/MRI scans performed in patients with presumed GBM progression. All PET/MRI examinations were clinically indicated and performed as part of routine standard-of-care imaging. Clinical classification was based on histopathology or imaging and clinical follow-up. SUVmax was measured in enhancing lesions. Group comparisons were assessed with Mann–Whitney U tests. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis, including derivation of an optimal cutoff using Youden’s index and validation of the previously published diagnostic threshold of 4.66 (Nabavizadeh et al.). Subgroup analyses compared diagnostic performance across institutions. RESULTS: Thirty-six patients with presumed GBM progression (Institution 1, n = 17; Institution 2, n = 19) provided 22 examinations classified as true tumor progression and 14 as treatment-related change. There were no significant differences in clinical or demographic study population characteristics between the two institutions. SUVmax was significantly higher in true tumor progression than in treatment-related change (median [interquartile range], 8.73 [5.86 -10.83] versus 3.71 [1.70 -4.67], p< .01). Combined ROC analysis demonstrated excellent diagnostic performance (AUC=0.90; 95% CI, 0.79–0.98). The optimal threshold of 5.7 yielded 86% sensitivity (0.70–0.99) and 86% specificity (0.64–0.99). Applying the published threshold of 4.66 produced similar results (AUC=0.90), with 91% sensitivity (0.71–0.99) and 71% specificity (0.42–0.92). A stratified analysis demonstrated comparable diagnostic performance across both institutions. CONCLUSIONS: [F18]-Fluciclovine PET/MRI demonstrated high diagnostic accuracy for differentiating true GBM progression from treatment-related changes, with consistent SUVmax thresholds across 2 institutions. These findings support the generalizability of [F18]-Fluciclovine PET as a biologically specific adjunct to conventional MR imaging for patients with presumed GBM progression. ABBREVIATIONS: [F18]-FACBC and [F18]-Fluciclovine= Trans-1-amino-3-[F18]-fluorocyclobutane-1-carboxylic acid; GBM=glioblastoma; IDH=Isocitrate Dehydrogenase; SUVmax=maximum standardized uptake value
- 1 December 2025
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 47 (6) , 1578-1586
Open AccessClinical Utility of [ 18 F]-Fluciclovine PET/MRI for Differentiating True Progression from Treatment-Related Changes in Patients with Glioblastoma
BACKGROUND AND PURPOSE: Differentiating true progression from treatment-related changes in patients with glioblastoma (GBM) remains a major diagnostic challenge. Amino acid PET tracers such as [F18]-Fluciclovine provide biologically specific information, but clinical real-world validation across institutions is limited. We aimed to evaluate the clinical diagnostic performance of [F18]-Fluciclovine PET/MRI for distinguishing true progression from treatment-related change in patients with presumed GBM progression across 2 academic centers. MATERIALS AND METHODS: In this retrospective, multi-institutional, IRB-approved study, we analyzed [F18]-Fluciclovine PET/MRI scans performed in patients with presumed GBM progression. All PET/MRI examinations were clinically indicated and performed as part of routine standard-of-care imaging. Clinical classification was based on histopathology or imaging and clinical follow-up. SUVmax was measured in enhancing lesions. Group comparisons were assessed with Mann–Whitney U tests. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis, including derivation of an optimal cutoff using Youden’s index and validation of the previously published diagnostic threshold of 4.66 (Nabavizadeh et al.). Subgroup analyses compared diagnostic performance across institutions. RESULTS: Thirty-six patients with presumed GBM progression (Institution 1, n = 17; Institution 2, n = 19) provided 22 examinations classified as true tumor progression and 14 as treatment-related change. There were no significant differences in clinical or demographic study population characteristics between the two institutions. SUVmax was significantly higher in true tumor progression than in treatment-related change (median [interquartile range], 8.73 [5.86 -10.83] versus 3.71 [1.70 -4.67], p< .01). Combined ROC analysis demonstrated excellent diagnostic performance (AUC=0.90; 95% CI, 0.79–0.98). The optimal threshold of 5.7 yielded 86% sensitivity (0.70–0.99) and 86% specificity (0.64–0.99). Applying the published threshold of 4.66 produced similar results (AUC=0.90), with 91% sensitivity (0.71–0.99) and 71% specificity (0.42–0.92). A stratified analysis demonstrated comparable diagnostic performance across both institutions. CONCLUSIONS: [F18]-Fluciclovine PET/MRI demonstrated high diagnostic accuracy for differentiating true GBM progression from treatment-related changes, with consistent SUVmax thresholds across 2 institutions. These findings support the generalizability of [F18]-Fluciclovine PET as a biologically specific adjunct to conventional MR imaging for patients with presumed GBM progression. ABBREVIATIONS: [F18]-FACBC and [F18]-Fluciclovine= Trans-1-amino-3-[F18]-fluorocyclobutane-1-carboxylic acid; GBM=glioblastoma; IDH=Isocitrate Dehydrogenase; SUVmax=maximum standardized uptake value
- 24 November 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (6) , 3216-3226
Ensuring patient safety: a comprehensive approach to radiological errors
Radiologic errors arise from the interaction of human fallibility and systemic weakness. Using a fatigue-related missed renal mass, this paper proposes a model that joins two complementary duties: ethical transparency through disclosure and apology, and system redesign grounded in Just Culture and human factors engineering. Together, these principles create a sustainable path toward safety. We outline common malpractice sources, offer practical guidance for disclosure and apology, and emphasize institutional strategies that transform individual error into system learning and patient-centered improvement.
- 24 November 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (6) , 3216-3226
Ensuring patient safety: a comprehensive approach to radiological errors
Radiologic errors arise from the interaction of human fallibility and systemic weakness. Using a fatigue-related missed renal mass, this paper proposes a model that joins two complementary duties: ethical transparency through disclosure and apology, and system redesign grounded in Just Culture and human factors engineering. Together, these principles create a sustainable path toward safety. We outline common malpractice sources, offer practical guidance for disclosure and apology, and emphasize institutional strategies that transform individual error into system learning and patient-centered improvement.
- Open Access
- 8 May 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (5)
Response to a novel type II RAF inhibitor in diffuse leptomeningeal glioneuronal tumor with BRAF fusion
Background: Diffuse leptomeningeal glioneuronal tumor (DL-GNT) is a rare disease which is more often diagnosed in children and adolescents than adults. Activation of the MAPK/ERK pathway is implicated in the majority of cases, and BRAF fusions are the most common genetic alteration. BRAF fusions result in dimerization and constitutive downstream MAPK/ERK activity, against which type I RAF inhibitors have limited efficacy. Type II RAF inhibitors stabilize RAF in an inactive conformation and inhibit both dimer protomers, thus inhibiting downstream MAPK/ERK activity in the setting of BRAF fusions. Case Presentation: A previously-healthy 33 year old man was diagnosed with DL-GNT, which harbored a pathogenic BRAF:KIAA1549 gene fusion. He was initially treated with a MEK inhibitor but developed drug-related cardiotoxicity. Without treatment, he developed significant functional limitations due to leptomeningeal disease. A compassionate use indication was pursued for an investigational CNS-penetrant type II BRAF inhibitor, tovorafenib. Within 3 months of initiating the medication, the patient experienced notable gains in functional status and with over 12 months of treatment has been able to rejoin recreational activities. Conclusions: This case highlights the importance of tumor molecular characterization, particularly in rare tumors, whereby identification of the BRAF:KIAA1594 gene fusion led to an appropriate selection of a type II BRAF inhibitor.
- 8 May 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (5)
Open AccessResponse to a novel type II RAF inhibitor in diffuse leptomeningeal glioneuronal tumor with BRAF fusion
Background: Diffuse leptomeningeal glioneuronal tumor (DL-GNT) is a rare disease which is more often diagnosed in children and adolescents than adults. Activation of the MAPK/ERK pathway is implicated in the majority of cases, and BRAF fusions are the most common genetic alteration. BRAF fusions result in dimerization and constitutive downstream MAPK/ERK activity, against which type I RAF inhibitors have limited efficacy. Type II RAF inhibitors stabilize RAF in an inactive conformation and inhibit both dimer protomers, thus inhibiting downstream MAPK/ERK activity in the setting of BRAF fusions. Case Presentation: A previously-healthy 33 year old man was diagnosed with DL-GNT, which harbored a pathogenic BRAF:KIAA1549 gene fusion. He was initially treated with a MEK inhibitor but developed drug-related cardiotoxicity. Without treatment, he developed significant functional limitations due to leptomeningeal disease. A compassionate use indication was pursued for an investigational CNS-penetrant type II BRAF inhibitor, tovorafenib. Within 3 months of initiating the medication, the patient experienced notable gains in functional status and with over 12 months of treatment has been able to rejoin recreational activities. Conclusions: This case highlights the importance of tumor molecular characterization, particularly in rare tumors, whereby identification of the BRAF:KIAA1594 gene fusion led to an appropriate selection of a type II BRAF inhibitor.
- Open Access
- 21 September 2023
- Published by Springer Nature in European Radiology
- Vol. 34 (4) , 2394-2404
Large variation in radiation dose for routine abdomen CT: reasons for excess and easy tips for reduction
Objective: To characterize the use and impact of radiation dose reduction techniques in actual practice for routine abdomen CT. Methods: We retrospectively analyzed consecutive routine abdomen CT scans in adults from a large dose registry, contributed by 95 hospitals and imaging facilities. Grouping exams into deciles by, first, patient size, and second, size-adjusted dose length product (DLP), we summarized dose and technical parameters and estimated which parameters contributed most to between-protocols dose variation. Lastly, we modeled the total population dose if all protocols with mean size-adjusted DLP above 433 or 645 mGy-cm were reduced to these thresholds. Results: A total of 748,846 CTs were performed using 1033 unique protocols. When sorted by patient size, patients with larger abdominal diameters had increased dose and effective mAs (milliampere seconds), even after adjusting for patient size. When sorted by size-adjusted dose, patients in the highest versus the lowest decile in size-adjusted DLP received 6.4 times the average dose (1680 vs 265 mGy-cm) even though diameter was no different (312 vs 309 mm). Effective mAs was 2.1-fold higher, unadjusted CTDIvol 2.9-fold, and phase 2.5-fold for patients in the highest versus lowest size-adjusted DLP decile. There was virtually no change in kV (kilovolt). Automatic exposure control was widely used to modulate mAs, whereas kV modulation was rare. Phase was the strongest driver of between-protocols variation. Broad adoption of optimized protocols could result in total population dose reductions of 18.6–40%. Conclusion: There are large variations in radiation doses for routine abdomen CT unrelated to patient size. Modification of kV and single-phase scanning could result in substantial dose reduction. Clinical relevance: Radiation dose-optimization techniques for routine abdomen CT are routinely under-utilized leading to higher doses than needed. Greater modification of technical parameters and number of phases could result in substantial reduction in radiation exposure to patients. Key Points: • Based on an analysis of 748,846 routine abdomen CT scans in adults, radiation doses varied tremendously across patients of the same size and optimization techniques were routinely under-utilized. • The difference in observed dose was due to variation in technical parameters and phase count. Automatic exposure control was commonly used to modify effective mAs, whereas kV was rarely adjusted for patient size. Routine abdomen CT should be performed using a single phase, yet multi-phase was common. • kV modulation by patient size and restriction to a single phase for routine abdomen indications could result in substantial reduction in radiation doses using well-established dose optimization approaches.
- 21 September 2023
- Published by Springer Nature in European Radiology
- Vol. 34 (4) , 2394-2404
Open AccessLarge variation in radiation dose for routine abdomen CT: reasons for excess and easy tips for reduction
Objective: To characterize the use and impact of radiation dose reduction techniques in actual practice for routine abdomen CT. Methods: We retrospectively analyzed consecutive routine abdomen CT scans in adults from a large dose registry, contributed by 95 hospitals and imaging facilities. Grouping exams into deciles by, first, patient size, and second, size-adjusted dose length product (DLP), we summarized dose and technical parameters and estimated which parameters contributed most to between-protocols dose variation. Lastly, we modeled the total population dose if all protocols with mean size-adjusted DLP above 433 or 645 mGy-cm were reduced to these thresholds. Results: A total of 748,846 CTs were performed using 1033 unique protocols. When sorted by patient size, patients with larger abdominal diameters had increased dose and effective mAs (milliampere seconds), even after adjusting for patient size. When sorted by size-adjusted dose, patients in the highest versus the lowest decile in size-adjusted DLP received 6.4 times the average dose (1680 vs 265 mGy-cm) even though diameter was no different (312 vs 309 mm). Effective mAs was 2.1-fold higher, unadjusted CTDIvol 2.9-fold, and phase 2.5-fold for patients in the highest versus lowest size-adjusted DLP decile. There was virtually no change in kV (kilovolt). Automatic exposure control was widely used to modulate mAs, whereas kV modulation was rare. Phase was the strongest driver of between-protocols variation. Broad adoption of optimized protocols could result in total population dose reductions of 18.6–40%. Conclusion: There are large variations in radiation doses for routine abdomen CT unrelated to patient size. Modification of kV and single-phase scanning could result in substantial dose reduction. Clinical relevance: Radiation dose-optimization techniques for routine abdomen CT are routinely under-utilized leading to higher doses than needed. Greater modification of technical parameters and number of phases could result in substantial reduction in radiation exposure to patients. Key Points: • Based on an analysis of 748,846 routine abdomen CT scans in adults, radiation doses varied tremendously across patients of the same size and optimization techniques were routinely under-utilized. • The difference in observed dose was due to variation in technical parameters and phase count. Automatic exposure control was commonly used to modify effective mAs, whereas kV was rarely adjusted for patient size. Routine abdomen CT should be performed using a single phase, yet multi-phase was common. • kV modulation by patient size and restriction to a single phase for routine abdomen indications could result in substantial reduction in radiation doses using well-established dose optimization approaches.
- 5 October 2022
- Published by SAGE Publications in Clinical Pediatrics
- Vol. 62 (5) , 492-497
An Eye-Opening Case of Persistent Headaches and Fever in a Teenager
- 5 October 2022
- Published by SAGE Publications in Clinical Pediatrics
- Vol. 62 (5) , 492-497
An Eye-Opening Case of Persistent Headaches and Fever in a Teenager
- 1 July 2020
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 40 (4) , 1148-1162
Temporal Bone Trauma: Typical CT and MRI Appearances and Important Points for Evaluation
Radiologists should be able to recognize typical CT and MRI appearances of temporal bone trauma, differentiate the entities that mimic these injuries, and adhere to the compulsory points for evalua... Temporal bone trauma is frequently encountered in the emergency department. Technologic advances have enabled timely acquisition of thin-section images and multiplanar reconstructions such that tem...
- 1 July 2020
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 40 (4) , 1148-1162
Temporal Bone Trauma: Typical CT and MRI Appearances and Important Points for Evaluation
Radiologists should be able to recognize typical CT and MRI appearances of temporal bone trauma, differentiate the entities that mimic these injuries, and adhere to the compulsory points for evalua... Temporal bone trauma is frequently encountered in the emergency department. Technologic advances have enabled timely acquisition of thin-section images and multiplanar reconstructions such that tem...
- 11 June 2020
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 41 (7) , 1193-1200
Distinguishing Extravascular from Intravascular Ferumoxytol Pools within the Brain: Proof of Concept in Patients with Treated Glioblastoma
BACKGROUND AND PURPOSE: Glioblastoma-associated macrophages are a major constituent of the immune response to therapy and are known to engulf the iron-based MR imaging contrast agent, ferumoxytol. Current ferumoxytol MR imaging techniques for localizing macrophages are confounded by contaminating intravascular signal. The aim of this study was to assess the utility of a newly developed MR imaging technique, segregation and extravascular localization of ferumoxytol imaging, for differentiating extravascular-from-intravascular ferumoxytol contrast signal at a delayed 24-hour imaging time point. MATERIALS AND METHODS: Twenty-three patients with suspected post-chemoradiotherapy glioblastoma progression underwent ferumoxytol-enhanced SWI. Segregation and extravascular localization of ferumoxytol imaging maps were generated as the voxelwise difference of the delayed (24 hours) from the early (immediately after administration) time point SWI maps. Continuous segregation and extravascular localization of ferumoxytol imaging map values were separated into positive and negative components. Image-guided biologic correlation was performed. RESULTS: Negative segregation and extravascular localization of ferumoxytol imaging values correlated with early and delayed time point SWI values, demonstrating that intravascular signal detected in the early time point persists into the delayed time point. Positive segregation and extravascular localization of ferumoxytol imaging values correlated only with delayed time point SWI values, suggesting successful detection of the newly developed extravascular signal. CONCLUSIONS: Segregation and extravascular localization of ferumoxytol MR imaging improves on current techniques by eliminating intrinsic tissue and intravascular ferumoxytol signal and may inform glioblastoma outcomes by serving as a more specific metric of macrophage content compared with uncorrected T1 and SWI techniques.
- 11 June 2020
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 41 (7) , 1193-1200
Distinguishing Extravascular from Intravascular Ferumoxytol Pools within the Brain: Proof of Concept in Patients with Treated Glioblastoma
BACKGROUND AND PURPOSE: Glioblastoma-associated macrophages are a major constituent of the immune response to therapy and are known to engulf the iron-based MR imaging contrast agent, ferumoxytol. Current ferumoxytol MR imaging techniques for localizing macrophages are confounded by contaminating intravascular signal. The aim of this study was to assess the utility of a newly developed MR imaging technique, segregation and extravascular localization of ferumoxytol imaging, for differentiating extravascular-from-intravascular ferumoxytol contrast signal at a delayed 24-hour imaging time point. MATERIALS AND METHODS: Twenty-three patients with suspected post-chemoradiotherapy glioblastoma progression underwent ferumoxytol-enhanced SWI. Segregation and extravascular localization of ferumoxytol imaging maps were generated as the voxelwise difference of the delayed (24 hours) from the early (immediately after administration) time point SWI maps. Continuous segregation and extravascular localization of ferumoxytol imaging map values were separated into positive and negative components. Image-guided biologic correlation was performed. RESULTS: Negative segregation and extravascular localization of ferumoxytol imaging values correlated with early and delayed time point SWI values, demonstrating that intravascular signal detected in the early time point persists into the delayed time point. Positive segregation and extravascular localization of ferumoxytol imaging values correlated only with delayed time point SWI values, suggesting successful detection of the newly developed extravascular signal. CONCLUSIONS: Segregation and extravascular localization of ferumoxytol MR imaging improves on current techniques by eliminating intrinsic tissue and intravascular ferumoxytol signal and may inform glioblastoma outcomes by serving as a more specific metric of macrophage content compared with uncorrected T1 and SWI techniques.
- Open Access
- 14 May 2020
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 41 (6) , 966-968
Asymptomatic COVID-19: What the Neuroradiologist Needs to Know about Pulmonary Manifestations
SUMMARY: Coronavirus disease 2019 (COVID-19) is an infectious disease with a high asymptomatic incidence. Asymptomatic infections within a population will inevitably lead to diagnosis via unrelated medical imaging. We report the case of an asymptomatic patient undergoing a spine CT examination for trauma who was incidentally found to have lung abnormalities later confirmed to be COVID-19. We aim to familiarize neuroradiologists with the spectrum of COVID-19 pulmonary manifestations that are likely to be observed on neck and spine CT imaging.
- 14 May 2020
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 41 (6) , 966-968
Open AccessAsymptomatic COVID-19: What the Neuroradiologist Needs to Know about Pulmonary Manifestations
SUMMARY: Coronavirus disease 2019 (COVID-19) is an infectious disease with a high asymptomatic incidence. Asymptomatic infections within a population will inevitably lead to diagnosis via unrelated medical imaging. We report the case of an asymptomatic patient undergoing a spine CT examination for trauma who was incidentally found to have lung abnormalities later confirmed to be COVID-19. We aim to familiarize neuroradiologists with the spectrum of COVID-19 pulmonary manifestations that are likely to be observed on neck and spine CT imaging.
- Open Access
- 1 May 2020
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 180 (5) , 666-675
Comparison of the Effectiveness of Single-Component and Multicomponent Interventions for Reducing Radiation Doses in Patients Undergoing Computed Tomography
Importance: Computed tomography (CT) radiation doses vary across institutions and are often higher than needed.Objective: To assess the effectiveness of 2 interventions to reduce radiation doses in patients undergoing CT.Design, Setting, and Participants: This randomized clinical trial included 864 080 adults older than 18 years who underwent CT of the abdomen, chest, combined abdomen and chest, or head at 100 facilities in 6 countries from November 1, 2015, to September 21, 2017. Data analysis was performed from October 4, 2017, to December 14, 2018.Interventions: Imaging facilities received audit feedback alone comparing radiation-dose metrics with those of other facilities followed by the multicomponent intervention, including audit feedback with targeted suggestions, a 7-week quality improvement collaborative, and best-practice sharing. Facilities were randomly allocated to the time crossing from usual care to the intervention.Main Outcomes and Measures: Primary outcomes were the proportion of high-dose CT scans and mean effective dose at the facility level. Secondary outcomes were organ doses. Outcomes after interventions were compared with those before interventions using hierarchical generalized linear models adjusting for temporal trends and patient characteristics.Results: Across 100 facilities, 864 080 adults underwent 1 156 657 CT scans. The multicomponent intervention significantly reduced proportions of high-dose CT scans, measured using effective dose. Absolute changes in proportions of high-dose scans were 1.1% to 7.9%, with percentage reductions in the proportion of high-dose scans of 4% to 30% (abdomen: odds ratio [OR], 0.82; 95% CI, 0.77-0.88; P < .001; chest: OR, 0.92; 95% CI, 0.86-0.99; P = .03; combined abdomen and chest: OR, 0.49; 95% CI, 0.41-0.59; P < .001; and head: OR, 0.71; 95% CI, 0.66-0.76; P < .001). Reductions in the proportions of high-dose scans were greater when measured using organ doses. The absolute reduction in the proportion of high-dose scans was 6.0% to 17.2%, reflecting 23% to 58% reductions in the proportions of high-dose scans across anatomical areas. Mean effective doses were significantly reduced after multicomponent intervention for abdomen (6% reduction, P < .001), chest (4%, P < .001), and chest and abdomen (14%, P < .001) CT scans. Larger reductions in mean organ doses were 8% to 43% across anatomical areas. Audit feedback alone reduced the proportions of high-dose scans and mean dose, but reductions in observed dose were smaller. Radiologist’s satisfaction with CT image quality was unchanged and high during all periods.Conclusions and Relevance: For imaging facilities, detailed feedback on CT radiation dose combined with actionable suggestions and quality improvement education significantly reduced doses, particularly organ doses. Effects of audit feedback alone were modest.Trial Registration: ClinicalTrials.gov Identifier: NCT03000751
- 1 May 2020
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 180 (5) , 666-675
Open AccessComparison of the Effectiveness of Single-Component and Multicomponent Interventions for Reducing Radiation Doses in Patients Undergoing Computed Tomography
Importance: Computed tomography (CT) radiation doses vary across institutions and are often higher than needed.Objective: To assess the effectiveness of 2 interventions to reduce radiation doses in patients undergoing CT.Design, Setting, and Participants: This randomized clinical trial included 864 080 adults older than 18 years who underwent CT of the abdomen, chest, combined abdomen and chest, or head at 100 facilities in 6 countries from November 1, 2015, to September 21, 2017. Data analysis was performed from October 4, 2017, to December 14, 2018.Interventions: Imaging facilities received audit feedback alone comparing radiation-dose metrics with those of other facilities followed by the multicomponent intervention, including audit feedback with targeted suggestions, a 7-week quality improvement collaborative, and best-practice sharing. Facilities were randomly allocated to the time crossing from usual care to the intervention.Main Outcomes and Measures: Primary outcomes were the proportion of high-dose CT scans and mean effective dose at the facility level. Secondary outcomes were organ doses. Outcomes after interventions were compared with those before interventions using hierarchical generalized linear models adjusting for temporal trends and patient characteristics.Results: Across 100 facilities, 864 080 adults underwent 1 156 657 CT scans. The multicomponent intervention significantly reduced proportions of high-dose CT scans, measured using effective dose. Absolute changes in proportions of high-dose scans were 1.1% to 7.9%, with percentage reductions in the proportion of high-dose scans of 4% to 30% (abdomen: odds ratio [OR], 0.82; 95% CI, 0.77-0.88; P < .001; chest: OR, 0.92; 95% CI, 0.86-0.99; P = .03; combined abdomen and chest: OR, 0.49; 95% CI, 0.41-0.59; P < .001; and head: OR, 0.71; 95% CI, 0.66-0.76; P < .001). Reductions in the proportions of high-dose scans were greater when measured using organ doses. The absolute reduction in the proportion of high-dose scans was 6.0% to 17.2%, reflecting 23% to 58% reductions in the proportions of high-dose scans across anatomical areas. Mean effective doses were significantly reduced after multicomponent intervention for abdomen (6% reduction, P < .001), chest (4%, P < .001), and chest and abdomen (14%, P < .001) CT scans. Larger reductions in mean organ doses were 8% to 43% across anatomical areas. Audit feedback alone reduced the proportions of high-dose scans and mean dose, but reductions in observed dose were smaller. Radiologist’s satisfaction with CT image quality was unchanged and high during all periods.Conclusions and Relevance: For imaging facilities, detailed feedback on CT radiation dose combined with actionable suggestions and quality improvement education significantly reduced doses, particularly organ doses. Effects of audit feedback alone were modest.Trial Registration: ClinicalTrials.gov Identifier: NCT03000751